93 related articles for article (PubMed ID: 20480164)
1. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab.
Kawashiri SY; Kawakami A; Sakamoto N; Ishimatsu Y; Eguchi K
Rheumatol Int; 2012 Dec; 32(12):4023-6. PubMed ID: 20480164
[TBL] [Abstract][Full Text] [Related]
2. Rate of severe and fatal infections in a cohort of patients with interstitial lung disease associated with rheumatoid arthritis: a multicenter prospective study.
Mena-Vázquez N; Redondo-Rodriguez R; Rojas-Gimenez M; Romero-Barco CM; Fuego-Varela C; Perez-Gómez N; Añón-Oñate I; Castro Pérez P; García-Studer A; Hidalgo-Conde A; Arnedo Díez de Los Ríos R; Cabrera-César E; Velloso-Feijoo ML; Manrique-Arija S; Calvo-Gutiérrez J; Gandía-Martínez M; Morales-Garrido P; Godoy-Navarrete FJ; Mouriño-Rodriguez C; Espildora F; Aguilar-Hurtado MC; Fernández-Nebro A
Front Immunol; 2024; 15():1341321. PubMed ID: 38605950
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab-induced pulmonary fibrosis in a patient with rheumatoid arthritis.
Silva S; Amarasena R; Moorcroft J; Rajakulenthiran T; Singh R
Clin Med (Lond); 2020 Mar; 20(Suppl 2):s57. PubMed ID: 32409376
[No Abstract] [Full Text] [Related]
4. Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease.
Otsuji N; Sugiyama K; Owada T; Arifuku H; Koyama K; Hirata H; Fukushima Y
Open Access Rheumatol; 2024; 16():127-135. PubMed ID: 38883149
[TBL] [Abstract][Full Text] [Related]
5. Lesson of the month 1: Septic arthritis with normal acute phase reactants and white cell count in a patient receiving tocilizumab.
Conway R; Orr C; McCarthy GM
Clin Med (Lond); 2017 Jun; 17(3):280-281. PubMed ID: 28572233
[TBL] [Abstract][Full Text] [Related]
6. Comment on: Impact of interstitial lung disease on clinical remission of rheumatoid arthritis: results from the IORRA cohort.
Shih PC
Rheumatology (Oxford); 2024 Apr; 63(4):e132-e133. PubMed ID: 37769247
[No Abstract] [Full Text] [Related]
7. Comment on: Impact of interstitial lung disease on clinical remission of rheumatoid arthritis: results from the IORRA cohort: Reply.
Sugano E; Tanaka E; Inoue E; Harigai M
Rheumatology (Oxford); 2024 Apr; 63(4):e134-e135. PubMed ID: 37769232
[No Abstract] [Full Text] [Related]
8. Improvement in joint inflammation is accompanied by reduction in arterial inflammation: Tocilizumab in rheumatoid arthritis.
Zureigat H; Civieri G; Abohashem S; Osborne MT; Solomon DH; Giles JT; Bathon J; Massarotti E; Unizony S; Tawakol A
J Nucl Cardiol; 2024 Mar; 33():101813. PubMed ID: 38266667
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate toxicity complicating a case of rheumatoid arthritis associated Interstitial Lung Disease: Lessons to learn.
Ikrou H; Salek M; Boustani S; Bouissar W; Wakrim S; Abdala S; Serhane H
Radiol Case Rep; 2024 Jun; 19(6):2218-2223. PubMed ID: 38523723
[TBL] [Abstract][Full Text] [Related]
10. Fatal pulmonary hemorrhage after taking anticoagulation medication.
Hammar SP
Respir Med Case Rep; 2015; 15():66-70. PubMed ID: 26236607
[TBL] [Abstract][Full Text] [Related]
11. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
Roubille C; Haraoui B
Semin Arthritis Rheum; 2014 Apr; 43(5):613-26. PubMed ID: 24231065
[TBL] [Abstract][Full Text] [Related]
12. Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis.
Wendling D; Vidon C; Godfrin-Valnet M; Rival G; Guillot X; Prati C
Joint Bone Spine; 2013 Dec; 80(6):670-1. PubMed ID: 23618802
[No Abstract] [Full Text] [Related]
13. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade.
Mohr M; Jacobi AM
Scand J Rheumatol; 2011; 40(5):400-1. PubMed ID: 21961704
[No Abstract] [Full Text] [Related]
14. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study.
Manfredi A; Cassone G; Furini F; Gremese E; Venerito V; Atzeni F; Arrigoni E; Della Casa G; Cerri S; Govoni M; Petricca L; Iannone F; Salvarani C; Sebastiani M
Intern Med J; 2020 Sep; 50(9):1085-1090. PubMed ID: 31661185
[TBL] [Abstract][Full Text] [Related]
15. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.
Akiyama M; Kaneko Y; Yamaoka K; Kondo H; Takeuchi T
Rheumatol Int; 2016 Jun; 36(6):881-9. PubMed ID: 27072347
[TBL] [Abstract][Full Text] [Related]
16. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
Md Yusof MY; Kabia A; Darby M; Lettieri G; Beirne P; Vital EM; Dass S; Emery P
Rheumatology (Oxford); 2017 Aug; 56(8):1348-1357. PubMed ID: 28444364
[TBL] [Abstract][Full Text] [Related]
17. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.
Picchianti Diamanti A; Markovic M; Argento G; Giovagnoli S; Ricci A; Laganà B; D'Amelio R
Ther Adv Respir Dis; 2017 Jan; 11(1):64-72. PubMed ID: 27733490
[TBL] [Abstract][Full Text] [Related]
19. Organizing Pneumonia Induced by Tocilizumab in a Patient with Rheumatoid Arthritis.
Gouveia PA; Ferreira ECG; Cavalcante Neto PM
Cureus; 2020 Feb; 12(2):e6982. PubMed ID: 32201660
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab for the treatment of patients with rheumatoid arthritis and interstitial lung diseases: a case series.
Manfredi A; Sebastiani M; Cassone G; Colaci M; Sandri G; Ferri C
Clin Exp Rheumatol; 2018; 36(2):342. PubMed ID: 29465372
[No Abstract] [Full Text] [Related]
[Next] [New Search]
